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PXPEDITED REVIEWS
he Cost Effectiveness of
mplantable Cardioverter-Defibrillators
esults From the Multicenter Automatic
efibrillator Implantation Trial (MADIT)-II
ack Zwanziger, PHD,* W. Jackson Hall, PHD,† Andrew W. Dick, PHD,* Hongwei Zhao, DSC,†
lvin I. Mushlin, MD, SCM,* Rebecca Marron Hahn, MPH,* Hongkun Wang, MA,†
ark L. Andrews, BBS,‡ Cathleen Mooney, MS,* Hongyue Wang, MA,† Arthur J. Moss, MD‡
ochester, New York
OBJECTIVES We sought to evaluate the cost implications of the implantable cardioverter-defibrillator
(ICD), using utilization, cost, and survival data from the Multicenter Automatic Defibrillator
Implantation Trial (MADIT)-II.
BACKGROUND This trial showed that prophylactic implantation of a defibrillator reduces the rate of mortality
in patients who experienced a previous myocardial infarction and low left ventricular ejection
fraction. Given the size of the eligible population, the cost effectiveness of the ICD has
substantial implications.
METHODS Our research comprises the cost-effectiveness component of the randomized controlled trial,
MADIT-II, based on utilization, cost, and survival information from 1,095 U.S. patients who
were assigned randomly to receive an ICD or conventional medical care. Utilization data were
converted to costs using a variety of national and hospital-specific data. The incremental
cost-effectiveness ratio (iCER) was calculated as the difference in discounted costs divided by
the difference in discounted life expectancy within 3.5 years. Secondary analyses included
projections of survival (using three alternative assumptions), corresponding cost assumptions,
and the resulting cost-effectiveness ratios until 12 years after randomization.
RESULTS During the 3.5-year period of the study, the average survival gain for the defibrillator arm was
0.167 years (2 months), the additional costs were $39,200, and the iCER was $235,000 per
year-of-life saved. In three alternative projections to 12 years, this ratio ranged from $78,600
to $114,000.
CONCLUSIONS The estimated cost per life-year saved by the ICD in the MADIT-II study is relatively high
at 3.5 years but is projected to be substantially lower over the course of longer time
horizons. (J Am Coll Cardiol 2006;47:2310–8) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.032Cardiology Foundation
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aeveral clinical trials have shown that implantable
ardioverter-defibrillators (ICDs) improve survival in pa-
ients with a spectrum of heart disease (1–8). The second
ulticenter Automatic Defibrillator Implantation Trial
MADIT)-II (5), conducted in 1997 to 2002, had a
elatively broad set of inclusion criteria that could have a
ajor impact because 32,000 to 66,000 people in the U.S.
nnually fit these criteria (9,10). Three studies (10–12) have
eported cost evaluations for MADIT-II–type patients,
ithout use of cost information from the trial. This report
ombines patient outcome and economic data from the U.S.
From the Departments of *Community and Preventive Medicine, †Biostatistics
nd Computational Biology, and the ‡Cardiology Division of the Department of
edicine, University of Rochester School of Medicine and Dentistry, Rochester,
ew York. Several authors (Dr. Hall, Dr. Dick, Mr. Zhao, Ms. Hahn, Mr. Andrews,
r. Moss) are significant participants on a research study funded by Guidant Corp.
MADIT-CRT). This study was supported by a grant from the Guidant Corporation
f St. Paul, Minnesota, to the University of Rochester. Dr. Zwanziger is now at the
chool of Public Health, University of Illinois at Chicago; Dr. Mushlin is now at the
eill School of Medicine, Cornell University.a
Manuscript received December 4, 2005; revised manuscript received March 2,
006, accepted March 16, 2006.atients in the MADIT-II study and presents an analysis of
he cost effectiveness of their ICD therapy.
ETHODS
he MADIT-II study. Eligibility requirements for the
ADIT-II study included a previous myocardial infarction
nd a left ventricular ejection fraction 30%, with no
lectrophysiological testing required. Patients were assigned
andomly to receive either an ICD or conventional medical
herapy (CONV), in a 3:2 ratio; approved ICD devices were
hose manufactured by Guidant Corporation (St. Paul,
innesota). The enrollment procedures, clinical follow-up,
nd results have been described previously (5). The
ADIT-II research protocol was approved by the institu-
ional review boards of the enrolling centers; all enrolled
atients gave written informed consent. Funding for the
tudy was provided by Guidant Corporation. The authors
re solely responsible for the study design, data collection,
nalysis, and interpretation of results.
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June 6, 2006:2310–8 Cost Effectiveness of ICDsThe cost-effectiveness analysis was based on 1,095 of the
,232 patients in the MADIT-II study, namely those from 69
.S. centers (omitting the five European centers [n  109],
wo U.S. centers [n  14] with grossly incomplete cost data,
nd 14 additional patients with missing cost data). Of the
,095 patients, there were 664 in the ICD arm and 431 in the
ONV arm; 17 of the former never received an ICD, and 23
f the latter had implantations during the trial. Baseline
haracteristics of the patients in the cost-effectiveness substudy
ere much the same as for all patients (5). All-cause mortality
as 90 (21%) in the CONV arm and 97 (15%) in the ICD arm
estimated hazard ratio [HR]  0.677).
ollection of utilization information. Patients were
cheduled for follow-up visits at one and three months after
andomization, at three-month intervals thereafter, and
ere contacted by phone during each intervening month.
he information gathered at each contact (clinic or phone)
ncluded:
number and duration of physician office visits by specialty
number and type of outpatient diagnostic tests and
procedures and ambulatory surgeries
dates and hospital name for each emergency room visit
and hospitalization
number and duration of other health care services,
including nursing home admissions, physical, speech, or
occupational therapies and podiatry
medications taken since the last clinic visit.
t each office visit or telephone contact, patients reviewed their
tilization for any period they missed. Study staff contacted the
Abbreviations and Acronyms
CONV  conventional therapy
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
iCER  incremental cost effectiveness ratio
MADIT-II  Second Multicenter Automatic
Defibrillator Implantation Trial
QALY  quality-adjusted life years
YOLS  years-of-life saved
able 1. Data Completion, by Treatment Arm
Type
CONV (n  431)
Total Follow-Up  729 yrs
Total*
Number
Incomplete† (%)
ospitalizations 530 17 (3.21%)
mergency room visits 256 15 (5.86%)
hysician visits 6,338 3 (0.05%)
utpatient tests/procedures 6,275 54 (0.86%)
edications 6,864 0 (0.00%)
ursing home stays 97 1 (1.03%)
ther (e.g., home health care) 713 68 (9.54%)Total number of services reported by patients. †Number of services for which a cost could
CONV  conventional therapy arm of the trial; ICD  implantable cardioverter-defibamed hospitals, provided the required patient authorizations,
nd requested the hospital bills.
Table 1 shows the completeness of the health care
tilization data collected for the MADIT-II study. The
argest proportion of expenditures was for hospital services
ith only 17 of 530 (CONV) and 25 of 1,450 (ICD)
npatient hospital bills missing. Similarly, small proportions
f other utilization data were not collected. Values for
issing data were imputed; for example, when hospital bills
ere missing, the costs were estimated using length of stay
nd average cost per day for that admission type.
alculating costs and charges. The methods used to trans-
ate utilization data into costs were those used inMushlin et al.
13), except that the costs for inpatient physician services were
stimated by regression models using data from Medicare
npatient and physician bills. These models generated the
redicted ratio of inpatient physician costs to hospital costs
or each admission. The physician costs associated with an
dmission are this predicted ratio multiplied by its hospital
osts.
tatistical methods. PRIMARY ANALYSES. All primary
nalyses were prespecified with patients assigned to arm on
n “intent-to-treat” basis. These analyses had a maximum of
.5 years of follow-up (with data from only 18 patients
eyond that) and are from a societal perspective. Costs were
ssembled on a daily basis, with period-specific costs (for
ospitalizations, for example) spread evenly over the appro-
riate period.
For survival, we used follow-up information until closeout—
ypically a month or so beyond the formal trial termination
but before any subsequent ICD implantation). Follow-up
anged from 11 days to 55 months, averaging 22 months.
nly one patient was lost to follow-up for survival infor-
ation, and then for only six months. As recommended
14), both costs and survival times were discounted—with
uture costs and benefits worth less than current ones—to
andomization using a 3% per annum discount rate. All
osts are expressed in 2001 dollars.
Thirty-two patients became inactive before trial termina-
ion, resulting in a shorter follow-up period for cost analysis;
ICD (n  664)
Total Follow-Up  1,170 yrs All
Total*
Number
Incomplete† (%)
Percent Service Type of
Total Non-Device Costs
1,450 25 (1.72%) 63.5%
454 14 (3.08%) 0.3%
10,582 0 (0.00%) 4.0%
12,548 31 (0.25%) 3.4%
11,215 1 (0.01%) 25.2%
39 0 (0.00%) 2.6%
1,457 121 (8.30%) 1.0%not be assigned or an imputation was used.
rillator.
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Cost Effectiveness of ICDs June 6, 2006:2310–8nly their survival status was determined at closeout. Their
ollow-up averaged 44% of the potential number, represent-
ng a loss of 2.2% of the total follow-up days in the study.
Arm-specific discounted mean costs and survival times
nd the resulting incremental cost-effectiveness ratio
iCER) and associated confidence limits were estimated by
ethods in (15), extended to accommodate differing follow-up
imes for cost and survival in some patients (16). We re-
stimated the iCER by the method used in the MADIT study
17), which is similar to that in Lin et al. (18).
ROJECTING TO A 12-YEAR TIME HORIZON. Projecting sur-
ival. To project arm-specific survival out to 12 years, using
aplan-Meier estimates for the first 3.5 years, we used the
ollowing life-table method. We determined the average
urvival probability for each of 12 successive years for a
ubset of the U.S. population, matched by age and gender to
he MADIT-II study population, using published data for
he U.S. (19). This survival curve was fit almost perfectly by
quadratic hazard rate model, with hazard rate increasing at
n accelerated rate over time (reflecting aging). We assumed
hat CONV arm patients would likewise have a quadratic
azard rate, proportional to that for the U.S. subpopulation,
uring the 12-year period. Using the CONV arm data
years 0 to 4), we estimated the conventional arm versus
.S. age-adjusted HR to be 4.54. Equivalently, the CONV
rm survival curve is exponential on an accelerated time
cale that reflects yearly increases in hazard rates for the
atched U.S. subpopulation. This model fit the available
ata well (with two goodness of fit tests each yielding p 
.6), but projections beyond 3.5 years are speculative.
To project survival in the ICD arm, we used three
lternative, but related, methods, depending on the choice
f the HR relative to CONV. For each, the HR at year 3.5
as fixed at 0.677, the data-based estimate. The three
cenarios for the ICD HR relative to CONV were:
) ICD1, where HR remains the same as that observed
during the trial;
) ICD2, where HR increases linearly after 3.5 years so
that at 12 years ICD survivors have the same risk as do
CONV survivors, which is consistent with an assump-
tion that the beneficial advantage of the ICD declines,
relative to a CONV population with patients at risk of
sudden cardiac death gradually dying off;
) ICD3, where HR increases faster after 3.5 years so that
the survival curves meet at 12 years, which is consistent
with an assumption of greater mortality risk among
survivors in the ICD arm than in the CONV arm after
7.1 years.
ecause of linear changes over the course of time, the
CD2-3 models have cubic hazard rates.
Projecting costs. We first conducted regression analyses of
onthly patient-specific costs (undiscounted and excluding
evice, implantation, and replacement costs for ICD-arm
atients). The regression model consisted of arm-specific fandom effects for patients (excluding initial and death
osts), and arm-specific fixed effects for costs in the first
onth and for the six-month period before death. We
riginally considered more detailed initial costs and death
osts, and time trends in monthly costs, but we found these
o be small and statistically insignificant.
We then used the fitted regression model to project
onthly costs beyond 3.5 years, multiplying the estimated
rm-specific monthly costs (discounted) by the estimated
robability of survival through that month, using the cor-
esponding survival models. Because time trends could not
e identified, cost projections for survivors do not increase
ith age, except that death costs become more likely with
ncreasing death rates. In the projections, we added in
enerator replacement costs of $27,414, based on generator
nd associated medical cost data from 32 early replacements.
eplacement costs, appropriately discounted, were assumed
o take place at years 5 and 10; to assess sensitivity to this
ssumption, we considered a 7-year replacement period for
he ICD1 scenario.
Projecting the iCER. For any time point horizon, the
rojected iCER is obtained as the differential (ICD minus
ONV) projected discounted accumulated cost up to the
orizon, divided by the corresponding projected discounted
ears-of-life saved (YOLS). We limited projections to 12
ears because assumptions about long-term survival, ICD
ffects, and costs become increasingly tenuous the longer the
rojection, but this period should be long enough to capture
uch of the potential lifetime implications. (This choice
lso avoided ending at generator replacement times, multi-
les of 5 [or 7] years.)
UBGROUP AND SENSITIVITY ANALYSES. We analyzed the
ollowing:
) comparing patients in several clinically significant
subgroups;
) including, for the survival component of the analysis,
the 137 patients with no cost data, bringing the total
number of patients to 1,232;
) removal of the costs of electrophysiologic testing from
all ICD arm patients (because this generally is not
required for an ICD implantation but was recom-
mended in the MADIT-II protocol);
) reduction of the initial and replacement ICD device
costs by 50%.
We examined outlier costs and found them to be reason-
bly balanced between the two arms. However, 10 patients
n the ICD arm had heart transplants whereas none of the
atients in the CONV arm did. For these 10 hospitaliza-
ions, costs averaged $117,800 but did not constitute the
xtreme cost hospitalizations, nor was the effect large when
veraged over all ICD-arm patients or over all months of
ollow-up.
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June 6, 2006:2310–8 Cost Effectiveness of ICDsESULTS
rimary analyses. Table 2 summarizes the medical care use
nd costs for patients in each arm. On average, the device
nd associated implantation costs for ICD patients who
eceived an implant totaled $32,578. Average monthly costs
ere higher for ICD patients—including the costs of any
evice-related adverse events ($1,489 vs. $1,357)—with all
tilization categories, particularly inpatient hospital services
$813 vs. $735), contributing to the difference. Costs were
ubstantially higher in the six months before a patient’s
eath. None of the differences in monthly costs between
reatment arms were statistically significant.
Table 3 presents the within-trial results. At 3.5 years,
here was a $39,200 (discounted) accumulated cost differ-
nce between the two arms. Patients in the ICD arm are
xpected to live two months longer within 3.5 years (0.167
iscounted YOLS). The iCER was $235,000/YOLS, with
95% confidence interval of $121,000 to $1,212,000/
OLS, the very large upper limit reflecting the small lower
imit on YOLS (0.033 years). The iCER calculated by the
lternative methodology (18), as in the MADIT study (17),
as $230,000/YOLS. The calculated iCERs over time
ppear in Figure 1.
rojecting to a 12-year time horizon. Figure 2 displays
ctual survival for the first 3.5 years and projects it 12 years
fter randomization for the CONV arm and for the three
CD scenarios described previously. At year 12, projected
able 2. Average Costs and Utilization, by Treatment Arm
Type
CONV
(n  431)
ICD
(n  664)
osts*
Defibrillator
Device‡ N/A $22,284
Implantation‡ N/A $10,294
Average monthly costs
Total costs (per month) $1,357† $1,489†
Hospital (per month) $735 $813
Medications (per month) $367 $390
Nursing home (per month) $24 $49
Other§ (per month) $231 $237
Costs associated with death
Average monthly costs for 6
months prior to death
$6,706 $8,477
(n  64) (n  67)
ospitalizations¶
Number per yr 0.80 1.03
Days per yr 5.28 6.81
Costs are expressed in 2001 dollars and are not discounted. †Including the costs
ssociated with device-related adverse events on an intent-to-treat basis. There were
62 such events in the ICD arm versus 10 in the CONV arm. ‡For inpatient
mplantations, implantation costs were estimated by the average costs incurred for
mplants in one- or two-day admissions. Listed figures are estimates for the 647 ICD
rm patients who received implants; when averaged over all 664 ICD arm patients,
he cost is $10,030 (multiplying by 647/664). Device costs were based on list prices for
he model implanted and are for the 647 patients with implants; when averaged over
ll 664 ICD arm patients, device costs are $21,713. Device and implantation costs for
3 CONV patients who had ICDs implanted during the trial are included in CONV
verage monthly costs. §Including physician visits, outpatient diagnostic and thera-
eutic procedures, ambulatory surgery, and home care. Including only those who
urvived 6 months past randomization. ¶Excluding one- or two-day admissions forY
CD implantations and two days of longer implantation admissions.
Abbreviations as in Table 1.urvival is 25.7%, 19.5%, or 13.4%, depending on the
ssumptions and the arm; the corresponding YOLS values
discounted) at year 12 are 1.048, 0.871, and 0.665 for
CD1 to ICD3, respectively.
The cost projections are based on a regression analysis of
ndiscounted monthly cost data that found three cost
omponents: 1) initial month cost (estimated as $10,335,
lus device cost of $21,713, for ICD arm patients and
1,142 for CONV arm patients); 2) average monthly costs
ubsequently ($1,186 for ICD, $1,033 for CONV—with no
vidence of increase over time); and 3) 6-month prior-to-
eath additional costs of $29,236 ($15,130 in the last
onth, $3,970 and $1,098 in each of for months 2 to 4 and
to 6, respectively). Death costs were highly variable and
ithout statistically significant differences between arms,
ut we used arm-specific monthly costs to achieve a
etter fit.
Figure 3 displays discounted cumulative costs, actual
alues until 3.5 years and projected values beyond, based on
he same four assumed trajectories. Projected values, based
n the regression formulae, also are plotted for the period up
o 3.5 years, demonstrating the quality of their fit. Periodic
ncreases in costs for the ICD occur when replacement
evices are implanted; otherwise, the increases in the two
rms are almost parallel. The three ICD curves largely overlap
ntil year 10. At year 12, discounted cumulative costs were
180,300, $177,400 and $173,700 for the ICD1 to ICD3
cenarios, as opposed to $97,900 for the CONV arm.
Figure 1 displays the corresponding iCER curves, which
ecrease with increasing time except for increases at years 5 and
0 with device replacement. The iCERs at year 12 for ICD1
o ICD3 versus CONV are $78,600, $91,300 and $114,000/
OLS, respectively. If generator replacements take place at
even-year intervals, the iCER at year 12 (ICD1 vs. CONV)
ould be $66,700/YOLS, a 15% reduction.
ubgroup and sensitivity analyses. We estimated the
CER in each of five pairs of subgroups shown in Table 4.
our of the ten subgroups—namely, age 65 years, New
ork Heart Association functional class II or greater, QRS
120, blood urea nitrogen 25 mg/dl—had a statistically
ignificant difference (between treatment arms) in life ex-
ectancy at 3.5 years, or equivalently, a significantly positive
able 3. Accumulated Discounted Costs, Discounted Life
xpectancy, and the iCER, at 3.5 Years
CONV ICD Difference 95% CI‡
iscounted total
costs*
44.9 84.1 39.2 29.9–48.5
ife expectancy* 2.725 2.892 0.167 0.033–0.301
CER† 235 121–1,212
Per patient, within 3.5 years, in thousands of dollars of costs and in years of life
xpectancy, discounted at 3% p.a. The life-expectancy difference is the years-of-life
aved. †Incremental cost-effectiveness ratio (iCER), in thousands of dollars per
ear-of-life saved; iCER  ratio of differences, (line 1)/(line 2). ‡Confidence interval
CI) for iCER computed by Fieller’s (16) method, using variances and covariance of
he differences.
Abbreviations as in Table 1.OLS; confidence limits are problematic when YOLS may
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Cost Effectiveness of ICDs June 6, 2006:2310–8e negative. For each of these four pairs of subgroups, the
ubgroup with the higher mortality risk had the higher
OLS and lower iCER. However, none of the comparisons
f differences between arms within a pair are statistically
ignificant.
Reinstatement of the 137 patients with no cost data led to
n estimated iCER of $211,000/YOLS (95% confidence
nterval $116,000 to $673,000) (16). The reduced iCER
nd upper confidence limit is due to greater ICD effective-
ess found in the European centers and the increased
ample size but assumes similar patterns of survival and
osts across patient groups with and without cost data.
Removing the costs of initial electrophysiologic studies,
or the 506 patients in the ICD arm who had them (average
osts  $1,259), reduced the iCER at 3.5 years to
229,000/YOLS, a 2.6% reduction. Reducing ICD device
osts by 50% resulted in an iCER of $166,000/YOLS at 3.5
ears, a 29% reduction.
ISCUSSION
oth the effectiveness and cost-effectiveness results from
andomized controlled trials are intended to provide infor-
ation for clinical policy. The results of this study reveal a
ilemma in presenting cost-effectiveness results from such
rials. Whereas the effectiveness results are largely self-
igure 1. Incremental cost-effectiveness ratios (iCERs) for various horizon
f 1, 1.5, 2, 2.5, 3, and 3.5 years, marked by circles. The vertical line segm
ines are iCERs derived from projected survival curves (this figure) and the
lightly higher than the fitted model projections because early replacemen
odel, with all replacement costs imposed at 5 and 10 years. Note that thufficient, demonstrating that the ICD reduces mortality for ohe MADIT-II study population, the cost-effectiveness data
re more difficult to interpret. The cost and benefit data are
bserved for a relatively short period, whereas it is lifetime
osts and benefits that policymakers need to calculate the
rue cost effectiveness of an intervention. A further compli-
ation is that, for interventions like the MADIT-II study
here the incremental costs are largely the result of the
nitial intervention but benefits continue to accrue, iCER
alls rapidly with time horizon (20). Thus, the within-trial
CER is a poor estimate of the lifetime value. This dilemma
as not as acute for previous ICD trials because their
ithin-study iCERs were much lower; their projected
CERs were not as significant in interpreting their policy
mplications (17,21,22). For example, the MADIT study
ost for four-year iCER was $27,000/YOLS (17) resulting
rom a combination of a much greater YOLS and higher
osts in the CONV patients. The MADIT-II study results
ring both the need for, and uncertainty of, these projec-
ions clearly to the fore.
Significant issues are certainly at stake. Implantable
ardioverter-defibrillators have been shown to substantially
educe the number of sudden cardiac deaths (1–8), but their
ostliness makes it essential that they be targeted to popu-
ations for whom they confer substantial benefits. Using the
enters for Medicare and Medicaid Services estimates (9)
ual and projected. The iCER was estimated from the data with horizons
a 95% confidence interval for the iCER at 3.5 years (Table 3). The other
ssion model for costs (Fig. 2). As in Figure 2, the actual iCER values are
s of implantable cardioverter-defibrillators were removed when fitting the
tical axis has a logarithmic scale.s, act
ent is
regref the MADIT-II study population in the U.S. (55,000 to
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June 6, 2006:2310–8 Cost Effectiveness of ICDs5,000 new cases yearly), our 12-year projections of incre-
ental costs ($78,600 to $114,000) suggest additional
nnual expenditures in excess of $5 billion.
With such large additional expenditures at stake, clinical
olicymakers, whether physicians making treatment deci-
ions or insurers making coverage decisions, must consider
he cost-effectiveness results in their considerations despite
heir inherent uncertainty. The iCER at 3.5 years, the time
orizon for the MADIT-II study, was $235,000/YOLS.
he relatively high estimate of the iCER is largely the result
f the high initial cost of implantation and the relatively
mall YOLS, the latter partially reflecting the underlying
eterogeneity of the MADIT-II study population and the
ignificant risks of nonarrhythmic death (40% of the classi-
able deaths in CONV patients were assigned to other
auses) (23). The heterogeneity in response appears clearly
n the subgroup analyses. Although the study was not
esigned for this purpose, these analyses suggest that the
CER is more favorable in higher-risk subgroups. It would
e important to confirm this finding in other studies and
ver a longer time horizon.
Given the limited usefulness of the within-trial iCER in
nforming policy, we developed three projection scenarios to
epresent the uncertainties implicit in any attempt to assess
he longer term effects of ICD implantation: ICD1, where
igure 2. Survival curves, actual and projected. For the first 3.5 years, the
mplantable cardioverter-defibrillator (ICD) and conventional-therapy (CO
he CONV survival curve has been projected assuming proportional hazard
.54. There are three projected ICD survival curves, ICD1 with hazard ra
ncreasing linearly to unity at 12 years, and ICD3 with the HR increasing
hoices. Years-of-life saved are the areas between ICD and CONV curvehe protective effect continues unabated—optimistic con- videring that other causes of death will have an increasing
ole with aging; ICD2, where it gradually disappears; and
CD3, where the ICD death rate grows to surpass that in
he conventional arm—which is pessimistic, with cumula-
ive mortality “catching up” at 12 years (8 years in Weiss
t al. [24]). We projected costs as if the data-based regres-
ion formula applies into the future. The corresponding
CERs at 12 years ranged from $78,600 to $114,000/
OLS. Given the uncertainties in knowledge currently
vailable, particularly on the long-term survival curve for the
ADIT-II study population, there is no guarantee that the
true” iCER would fall in that range.
The BlueCross-BlueShield study (11), a recent revision
f it (12), and a recent Duke study (10) provide useful
omparisons, using different methodologies applied to pre-
iously published MADIT-II study survival results. The
CBS Markov decision model approach (11) was based on
he MADIT-II study cause-specific mortality data but with
ost data taken from non-MADIT study sources. Lifetime
CER was estimated to be $36,700/YOLS, with corre-
ponding values at 3.5 and 12 years, decreasing from
178,900 to $49,600/YOLS (G. Sanders, personal commu-
ication, November 2004). Their model-based 3.5-year
CER was 24% lower than our fully data-based value. Our
CD1 scenario with a seven-year replacement period pro-
urves are the Kaplan-Meier estimates of the probability of survival in the
arms, based on 1,095 patients in this cost study. From 3.5 years onward,
h an age- and gender-matched U.S. subpopulation, with a hazard ratio of
lative to CONV equal to 0.677 throughout, ICD2 with this hazard ratio
4 at 12 years, reaching 1.0 at 7.1 years; see the text for rationales for thesetwo c
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tes reides the most direct comparison of their 12-year estimates,
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Cost Effectiveness of ICDs June 6, 2006:2310–8oth assuming a continuing protective effect. Their
49,600/YOLS is lower than our estimate ($66,700/YOLS)
y a similar proportion (26%).
The recent revision (12) used all-cause mortality, some
evision of costs (derived from non-MADIT study sources),
nd a five-year replacement period, and estimated a
39,000/YOLS lifetime iCER. Their cost projections, for
oth arms, remain substantially below our patient-based
alues, with $57,500 (2005 dollars) lifetime costs in the
igure 3. Cumulative discounted costs, actual and projected. Actual cumu
ICD) and conventional-therapy (CONV) arms up to 3.5 years. Projected
ears; up to 3.5 years, they use the regression model for costs together wi
ariations for the ICD arm projections, corresponding to three assumption
ctual ICD arm costs are slightly higher than the projected values because, i
eriod were removed (to fit a regression model), and all replacement costs
rm curves at those times. The jump near the origin is caused by the initi
able 4. Subgroup Analyses of Cost, Life Expectancy, and iCER
Subgroup n* Cost Difference† (SE
ge 65 yrs 594 35.3 (4.4)
ge 65 yrs 501 42.9 (7.4)
YHA functional class II 677 33.2 (7.1)
YHA functional class I 403 46.1 (7.0)
RS 120 558 46.1 (6.4)
RS 120 527 32.0 (7.4)
UN 25 mg/dl 337 36.4 (6.8)
UN 25 mg/dl 753 38.6 (5.9)
VEF 25 754 44.3 (4.7)
VEF 25 341 26.1 (13.0)
Patients with missing baseline information omitted. †ICD minus CONV, in $1,0
ears-of-life saved (YOLS)  0 vs.  0 (YOLS  life expectancy [LE] difference)—
and hence the incremental cost-effectiveness ratio (iCER) is not bounded above), the
BUN  blood urea nitrogen; LVEF  left ventricular ejection fraction; NYHA  New
n Table 1.ontrol group substantially lower than even our $97,900
2001 dollars) at 12 years (and we have not allowed for any
ncrease in costs with aging).
The Duke study (10) was based on up to 15 years of cost
nd survival data for a MADIT-II study-eligible group of
uke University Medical Center patients. The ICD “com-
arison group” experience was generated assuming an HR
f 0.69 forever and non-ICD costs identical to those for
on-ICD patients. Lifetime and 12-year iCERs were
discounted costs are plotted for the implantable cardioverter-defibrillator
are based on a regression model and plotted over the range from 0 to 12
plan-Meier estimates of survival, whereas after 3.5 years, there are three
ut projected survival, and one CONV arm projection (Fig. 1 legend). The
jections, the costs of 32 replacement ICDs that occurred in the observation
assumed to occur at exactly 5 and 10 years, resulting in jumps in the ICD
D implantation.
.5 Years
LE Difference‡ (SE) iCER 95% CI for iCER
0.266 (0.104)§ 133 71–569
0.049 (0.079) 870 186–
0.203 (0.093)§ 164 70–1,619
0.126 (0.099) 366 133–
0.235 (0.101)§ 196 96–1,219
0.096 (0.093) 334 95–
0.323 (0.148)§ 113 55–967
0.110 (0.071) 353 142–
0.162 (0.085) 274 131–
0.178 (0.118) 147 3–
counted). ‡ICD minus CONV, in years (discounted). §p value 2.5% for testing
statistically significant treatment effect. When the YOLS is not significantly positive
ence interval (CI) is calculated under an assumption that the true YOLS is positive.lative
costs
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June 6, 2006:2310–8 Cost Effectiveness of ICDs50,500/YOLS and $79,900/YOLS, respectively. Their
2-year value was almost identical to ours for ICD1 (also
ith a persisting ICD effect). Applying the mean of the
atios between 12-year and lifetime iCERs of these two
tudies (1.47) to our 12-year value suggests an estimated
ifetime iCER in the $50,000 to $100,000/YOLS range.
Each of these studies assumed identical (nondevice) costs
n the two arms, whereas we found higher costs in ICD
urvivors than in CONV survivors, possibly the result of an
xcess of hospitalizations for heart failure in the ICD arm
Moss et al. [5]). These discrepancies confirm the difficulties
n: 1) basing estimates on data from different source, and 2)
ong-term extrapolations.
We have not translated into iCERs based on quality-
djusted life-years (QALYs). Some studies have done so
omewhat arbitrarily, e.g., in Sanders et al. (12), it was
ssumed that QALYs averaged 0.80 at baseline with later
eductions with aging, resulting in lifetime YOLS being
educed by a factor of 0.73 when converted to QALYs. By
ontrast, in the MADIT-II study, QALYs at baseline
veraged only 0.64 (K. Noyes, unpublished observations,
anuary 2006). Of necessity, iCERs in QALYs will be
reater.
Using iCERs as $/QALY rather than $/YOLS leads to
alues higher than the conventional limit for cost effective-
ess ($50,000 to 100,000 per QALY), but it is not clear
hether generally accepted medical practices are, or should
e, within these limits. For example, the National Heart,
ung, and Blood Institute Adult Treatment Panel III
uidelines recommend cholesterol-lowering treatments with
CERs that are substantially higher than $100,000 per
ALY (25). Furthermore, these limits have been chal-
enged on conceptual grounds since they have not changed
ver time with per capita income and medical prices, key
eterminants of the value of a YOLS (26,27). Clearly, a
reater consensus is needed as to a threshold value that would
ndicate whether or not an intervention is cost effective.
The large uncertainties that policymakers must confront
an be reduced with better estimates of the ICD effects on
ong-term survival and on costs, especially by clinically
ignificant subpopulations. In the interim, policy makers
ill have to apply the available knowledge for decisions as to
ow to best use this promising new technology.
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